Strides & TLC partner to launch Amphotericin B Liposome for injection

The global pharmaceutical company, Strides Pharma Science Limited and TLC, a clinical‐stage speciality pharmaceutical company announced on Thursday that Central Drugs Standard Control Organisation (CDSCO) of India has approved TLC’s new drug application (NDA) of Amphotericin B Liposome for injection 50 mg.  

The drug, known as Ampho TLC in India, will be imported from Taiwan by Stelis Biopharma Private Limited, the biotech arm of Strides Group, to aid in the country’s emergency of acute liposomal amphotericin B shortage. It will then be launched and distributed in India immediately by Strides.  

Ampho TLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as Mucormycosis, which has seen an increasing number of cases in the country. The drug is approved in Taiwan and has been marketed & sold for several years, with a steady increase in the market share each year.  

Speaking on the development, Dr R Ananthanarayanan, CEO & Managing Director at Strides stated that the approval from CDSCO allows the company to immediately import and distribute the product in India and also, helping to ease the crisis arising out of an unprecedented rise in the COVID‐19-related Mucormycosis cases. 

In the early trading session on Friday, the shares of  Strides Pharma Science Limited were trading at Rs 814.15, up by 0.84 per cent against a 0.45 per cent gain in the benchmark index. Its 52-week high and the 52-week low is Rs 1000 and Rs 387.70, respectively on BSE.